News Gilead ups its US investment plans by $11 billion Gilead Sciences has joined the list of pharma groups hiking their capital investment plans in the US.
News FDA ramps up unannounced inspections of foreign facilities Trump orders the FDA to ease the commissioning of domestic manufacturing facilities, as the regulator announces more unannounced foreign inspections.
News GSK "well positioned" to weather pharma tariffs GSK has said it is not too worried about the impact of potential pharma-specific US tariff rules as it posts a solid set of first-quarter results.
News AZ backs up threat of manufacturing shift from Europe AstraZeneca has said it is considering a shift in the production of some medicines from Europe to the US in order to sidestep potential tariffs.
News AbbVie makes its tariffs-driven investment play AbbVie has become the latest pharma group to make a big capital investment announcement in the US and court favour with the Trump administration.
News MSD has gauged its financial hit from Trump tariffs MSD expects to see an additional $200m layered onto its costs this year as a result of President Trump's tariffs, ahead of any pharma-specific levy.
News Beren's Niemann-Pick drug Lembaz cleared by FDA The FDA has approved Beren's Lembaz for Niemann-Pick disease type C, the first drug shown to extend survival in the ultra-rare inherited disorder.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.